COMy 2020 | The future of immunotherapies for multiple myeloma
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses the future of multiple myeloma treatment. There have been revolutions in immunotherapy including monoclonal antibodies, CAR T-cells and bispecific antibodies. CAR T-cells have shown a good response in refractory myeloma and will be interesting to see their use in earlier lines of therapy. However, the affordability of CAR T-cells remains a challenge. Preliminary studies of bispecific antibodies are promising. Other agents are on the horizon, for example, selinexor, venetoclax and melflufen. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.
Disclosures
Research support : Amgen, Janssen
Honorarium: BMS, Janssen, Amgen, Genentech, Astra Zeneca
